High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)
Hisham Abdel-Azim(Loma Linda University Medical Center), Michael A. Pulsipher(Primary Children's Hospital), Troy C. Quigg(CHRISTUS Transplant Institute), Kevin O. McNerney(Children's Hospital of Philadelphia), Jordan Milner, Alfred P. Gillio(University Medical Center), Emi Caywood(Alfred I. duPont Hospital for Children), Vanessa A. Fabrizio(Children's Hospital Colorado), Jeffrey S. Huo, Ulrich Duffner(Michigan United), Rabi Hanna(Cleveland Clinic), Sajad Khazal(The University of Texas MD Anderson Cancer Center), Kris M. Mahadeo(Duke University), Jonathan D. Fish(Hofstra University), Amy K. Keating(Boston Children's Hospital), Yueh‐Yun Chi(University of Southern California), Jorge Galvez Silva(Miami Children's Hospital), Jodi Skiles(Indiana University School of Medicine), Dana Salzberg, Aliza Gardenswartz(Hackensack University Medical Center), Nahal Lalefar(University of California, San Francisco), Christine S. Higham(University of California, San Francisco), Lisa Madden(CHRISTUS Transplant Institute), Neena Kapoor(University of Southern California), Rachel Phelan(Children's Hospital of Wisconsin), Shalini Shenoy(Washington University in St. Louis), Heather E. Stefanski(National Marrow Donor Program), J. Gregory Dolan(University of Utah)
Cited by 2
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369